Detalhe da pesquisa
1.
Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.
Pharmacogenet Genomics
; 26(9): 403-13, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27187662
2.
Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.
Ther Drug Monit
; 36(3): 302-9, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24345815
3.
Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis.
PLoS One
; 10(10): e0141266, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26484865
4.
Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders.
Pharmgenomics Pers Med
; 7: 121-7, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24868171
5.
Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of γ-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis.
PLoS One
; 9(11): e111066, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25372290